FUTURE研究:难治性膀胱过度活动症女性侵入性尿动力学检查的有效性与成本效果优越性随机试验
FUTURE研究是一项实用性、多中心、优越性随机对照试验,计划在英国约60家二级/三级医院招募1096名≥18岁难治性OAB或急迫性混合性尿失禁女性,比较尿动力学+综合临床评估与单纯综合临床评估。主要结局为随机化后15个月患者报告成功率(PGI-I),主要经济结局为15个月每获得质量调整生命年的增量成本,分析采用意向性治疗。
要点
- OAB影响英国12-14%成年女性,25-40%初始治疗失败为难治性OAB。
- 指南多推荐侵入性尿动力学确认逼尿肌过度活动后再行侵入性治疗,但高达45%病例可能无DO证据。
- FUTURE研究旨在评估常规尿动力学是否改善难治性OAB女性的患者报告结局并具成本效果。
核心结论
- FUTURE研究将回答常规尿动力学能否改善难治性OAB女性的治疗结局及其成本效果。
研究设计与样本
- 实用性、多中心、优越性随机对照试验,计划从英国约60家二级/三级医院招募1096名≥18岁难治性OAB或急迫性混合性尿失禁女性。
- 纳入标准:保守和药物治疗失败/不能耐受;所有同意者基线、3、6、15个月完成问卷。
- 主要分析采用意向性治疗,结果以估计值和95%CI呈现。
主要发现
- 原文未报告研究结果,仅描述研究设计与背景。
关键数值与推荐
- 主要结局:随机化后15个月患者报告成功率,采用Patient Global Impression of Improvement测量。
- 主要经济结局:15个月每获得质量调整生命年的增量成本。
- 次要结局包括不良事件、其他泌尿症状影响和健康相关生活质量。
临床怎么用
- 研究结果将 informing 患者、临床医生和政策制定者关于难治性OAB女性常规尿动力学是否改善治疗结局及是否具成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overactive bladder (OAB) syndrome is a symptom complex affecting 12-14% of the UK adult female population. Symptoms include urinary urgency, with or without urgency incontinence, increased daytime urinary frequency and nocturia. OAB has a negative impact on women's social, physical, and psychological wellbeing. Initial treatment includes lifestyle modifications, bladder retraining, pelvic floor exercises and pharmacological therapy. However, these measures are unsuccessful in 25-40% of women (refractory OAB). Before considering invasive treatments, such as Botulinum toxin injection or sacral neuromodulation, most guidelines recommend urodynamics to confirm diagnosis of detrusor overactivity (DO). However, urodynamics may fail to show evidence of DO in up to 45% of cases, hence the need to evaluate its effectiveness and cost-effectiveness. FUTURE (Female Urgency, Trial of Urodynamics as Routine Evaluation) aims to test the hypothesis that, in women with refractory OAB, urodynamics and comprehensive clinical assessment is associated with superior patient-reported outcomes following treatment and is more cost-effective, compared to comprehensive clinical assessment only. METHODS: FUTURE is a pragmatic, multi-centre, superiority randomised controlled trial. Women aged ≥ 18 years with refractory OAB or urgency predominant mixed urinary incontinence, and who have failed/not tolerated conservative and medical treatment, are considered for trial entry. We aim to recruit 1096 women from approximately 60 secondary/tertiary care hospitals across the UK. All consenting women will complete questionnaires at baseline, 3 months, 6 months and 15 months post-randomisation. The primary outcome is participant-reported success at 15 months post-randomisation measured using the Patient Global Impression of Improvement. The primary economic outcome is incremental cost per quality-adjusted life year gained at 15 months. The secondary outcomes include adverse events, impact on other urinary symptoms and health-related quality of life. Qualitative interviews with participants and clinicians and a health economic evaluation will also be conducted. The statistical analysis of the primary outcome will be by intention-to-treat. Results will be presented as estimates and 95% CIs. DISCUSSION: The FUTURE study will inform patients, clinicians and policy makers whether routine urodynamics improves treatment outcomes in women with refractory OAB and whether it is cost-effective. TRIAL REGISTRATION: ISRCTN63268739 . Registered on 14 September 2017.
引用
- Abdel-Fattah M, Chapple C, Guerrero K, et al. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms. Trials. 2021. PMID: 34702331. doi:10.1186/s13063-021-05661-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。